Fig. 9

Mitochondrial p53 constructs are tested in combination with paclitaxel in Kuramochi. (a) No drug (transfection only) group was added as the control (no paclitaxel). (b) The respective gene construct was used in combination with 30 nM paclitaxel. (c) (c) 60 nM paclitaxel was used in combination treatment. (d) The apoptotic activities from panel (a) to (c) are compared across different paclitaxel concentrations. The cells were transfected with the respective gene constructs, and the drugs were added 4 h after transfection at 2 different doses (100 nM and 200 nM). 48 h post-transfection, the cells were collected and analyzed using 7-AAD assay (48 h post-transfection). Error bars represent standard deviations from triplicates (n = 3). ***p < 0.001